



Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")

ARECOR TO PRESENT AT BIOTRINITY 2021

Cambridge, UK, 22 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that its CEO, Sarah Howell, will give a Company presentation at [BioTrinity](#) 2021.

[BioTrinity](#) is a highly regarded biopartnering and investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.

[BioTrinity](#) 2021 will be delivered live in a hybrid format at Bishopsgate, London and via a dedicated virtual platform on Monday 21 and Tuesday 22 June in person, with presentations available through the [BioTrinity](#) virtual platform until Friday 25 June.

Dr Sarah Howell, Chief Executive Officer, will present a 5-minute showcase at [BioLaunchPad](#) on Tuesday 22 June at 11:40 BST.

A copy of the presentation will also be made available on Arecor's website – www.arecor.com

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com



Notes to Editors

About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.areacor.com